GSK2593074A

• CAT Number: I019304
• CAS Number: 1337531-06-2
• Molecular Formula: C₂₇H₂₃N₅OS
• Molecular Weight: 465.57
• Purity: ≥95%
• Storage: Store at -20°C
• IUPAC Name: 1-[5-[4-amino-7-(1-methylpyrazol-4-yl)thieno[3,2-c]pyridin-3-yl]-2,3-dihydroindol-1-yl]-2-phenylethanone
• InChI: InChI=1S/C27H23N5OS/c1-31-15-20(13-30-31)21-14-29-27(28)25-22(16-34-26(21)25)18-7-8-23-19(12-18)9-10-32(23)24(33)11-17-5-3-2-4-6-17/h2-8,12-16H,9-11H2,1H3,(H2,28,29)
• InChIKey: LIGGMBSSOOVGAE-UHFFFAOYSA-N
• SMILES: CN1C=C(C=N1)C2=CN=C(C3=C2SC=C3C4=CC5=C(C=C4)N(CC5)C(=O)CC6=CC=CC=C6)N

GSK2593074A（Cat No.:I019304）, also known as GSK’074, is a selective and potent inhibitor of the human sodium-dependent glucose cotransporter 2 (SGLT2), which is a key target for the treatment of type 2 diabetes mellitus. GSK2593074A acts by inhibiting glucose reabsorption in the proximal renal tubule, leading to increased glucose excretion in the urine. It has been shown to improve glycemic control and reduce body weight in preclinical and clinical studies. GSK2593074A is a promising drug candidate for the treatment of type 2 diabetes mellitus and related metabolic disorders.

Reference

[1]. Zhou T, et al. Identification of a novel class of RIP1/RIP3 dual inhibitors that impede cell death and inflammation in mouse abdominal aortic aneurysm models. Cell Death Dis. 2019 Mar 6;10(3):226.